UCB Pharma (Germany)
In research, UCB Pharma (Germany) stands highest in Medicine (#10,480 of 17,978 worldwide) and Health Sciences (#12,622 of 20,462 worldwide), over all time.
- World rank, all time
- #21,936 of 42,892
- Rank in Germany
- #1,041 of 2,077
- Research works
- 308 ▼ 16% vs 2013–17
- Citations
- 8.2k 26.6 per fractional work
- Top-10% rate
- 14.6% record average 16.5%
- Open access
- 28% world 28%
What is UCB Pharma (Germany) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #10,480 of 17,978 | 17.6% | 191 | |
| Health SciencesDomain | #12,622 of 20,462 | 17.4% | 201 |
Each strip is that field’s whole ranked pool, with the notch where UCB Pharma (Germany) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 8.1×. Every wedge is a field page.
- Immunology and Microbiology 8.1×
- Business, Management and Accounting 4.5×
- Medicine 2.7×
- Economics, Econometrics and Finance 1.5×
- Veterinary 1.5×
- Neuroscience 1.4×
- Energy 1.0×
- Dentistry 0.9×
- Biochemistry, Genetics and Molecular Biology 0.8×
- Decision Sciences 0.8×
- Chemistry 0.8×
- Health Professions 0.8×
- Pharmacology, Toxicology and Pharmaceutics 0.7×
- Mathematics 0.7×
- Psychology 0.4×
- Nursing 0.2×
- Agricultural and Biological Sciences 0.2×
- Engineering 0.2×
- Social Sciences 0.2×
- Computer Science 0.2×
- Environmental Science 0.1×
- Arts and Humanities 0.1×
Who are the top researchers at UCB Pharma (Germany)?
Ranked on the composite score, Joachim Freitag, Bengt Hoepken and Babak Boroojerdi lead among researchers whose main affiliation is UCB Pharma (Germany).
- 1 Joachim Freitag Germany · #406,523 worldwide 60 citations · 20 works
- 2 Bengt Hoepken Germany · #700,177 worldwide 21 citations · 17 works
- 3 Babak Boroojerdi Germany · #1,121,767 worldwide 23 citations · 32 works
- 4 T. Kumke Germany · #1,521,153 worldwide 5 citations · 20 works
Which keywords describe research at UCB Pharma (Germany)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Digital Transformation, Leadership, Organizational Change, Autoantibodies, Inflammation, Management, Regulatory T Cells and Inflammatory Cytokines.
- Monoclonal Antibodies
- Status Epilepticus
- Rheumatoid Arthritis
- Customer Experience
- Surgery
- Neurobiology
- Myasthenia Gravis
- Genetics
- Strategic Innovation
- Immunotherapy
- Ankylosing Spondylitis
- Socio-Technical Systems
- Prognosis
- Antiepileptic Drugs
- IL-17
- Inflammatory Cytokines
- Regulatory T Cells
- Epidemiology
- Organizational Change
- Inflammation
- Digital Transformation
- Leadership
- Autoantibodies
- Management
- Immune System
- TGF-ß
- TH17 Cells
- Agility
- Quality of Life
- Sustainable Development
- Spondyloarthritis
- Industrial Psychology
- Epilepsy
- Neurological Disorders
- Thymic Tumors
- Classification
- Business Models
- Mobile Health
- Seizures
- Cytokines
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Digital Transformation8▲ 26×3 topics
- Inflammation6▲ 5.0×17 topics
- Leadership6▲ 21×2 topics
- Organizational Change6▲ 140×2 topics
- Autoantibodies5▲ 42×8 topics
- Epidemiology5▲ 2.2×18 topics
- Management4▲ 8.7×9 topics
- Regulatory T Cells4▲ 59×3 topics
- Immune System4▲ 28×2 topics
- Inflammatory Cytokines4▲ 81×2 topics
- TGF-ß4▲ 43×2 topics
- IL-174▲ 191×1 topic
- TH17 Cells4▲ 191×1 topic
- Antiepileptic Drugs3▲ 75×2 topics
- Agility3▲ 393×1 topic
- Prognosis3▲ 16×4 topics
- Quality of Life3▲ 3.8×8 topics
- Socio-Technical Systems3▲ 230×1 topic
- Sustainable Development3▲ 3.4×2 topics
- Ankylosing Spondylitis3▲ 184×1 topic
- Spondyloarthritis3▲ 184×1 topic
- Immunotherapy3▲ 7.1×7 topics
- Industrial Psychology3▲ 729×1 topic
- Strategic Innovation3▲ 1525×1 topic
- Epilepsy3▲ 44×3 topics
- Genetics3▲ 6.7×5 topics
- Neurological Disorders3▲ 8.3×8 topics
- Myasthenia Gravis2▲ 221×1 topic
- Thymic Tumors2▲ 221×1 topic
- Neurobiology2▲ 16×3 topics
- Classification2▲ 8.6×2 topics
- Surgery2▲ 11×2 topics
- Business Models2▲ 51×1 topic
- Customer Experience2▲ 24×1 topic
- Mobile Health2▲ 27×2 topics
- Rheumatoid Arthritis2▲ 38×2 topics
- Seizures2▲ 60×1 topic
- Status Epilepticus2▲ 79×1 topic
- Cytokines2▲ 11×3 topics
- Monoclonal Antibodies2▲ 35×3 topics
Which research topics does UCB Pharma (Germany) publish most on?
By volume in 2022–2025: Psoriasis: Treatment and Pathogenesis, Corporate Management and Leadership, Spondyloarthritis Studies and Treatments and Organizational Management and Change.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Psoriasis: Treatment and Pathogenesis Immunology 4 works
- 2 Corporate Management and Leadership Organizational Behavior and Human Resource Management 3 works
- 3 Spondyloarthritis Studies and Treatments Rheumatology 3 works
- 4 Organizational Management and Change Organizational Behavior and Human Resource Management 3 works
- 5 Myasthenia Gravis and Thymoma Neurology 2 works
- 6 Epilepsy research and treatment Psychiatry and Mental health 2 works
- 7 Digital Innovation in Industries Management of Technology and Innovation 2 works
- 8 Rheumatoid Arthritis Research and Therapies Rheumatology 2 works
- 9 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 10 Pharmacological Effects and Toxicity Studies Pediatrics, Perinatology and Child Health 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has UCB Pharma (Germany)'s research output changed?
Output in 2018–2022 was 16% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Monheim am Rhein
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.